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ABSTRACT
Targeted genome enrichment is a powerful tool for
making use of the massive throughput of novel
DNA-sequencing instruments. We herein present a
simple and scalable protocol for multiplex amplifi-
cation of target regions based on the Selector tech-
nique. The updated version exhibits improved
coverage and compatibility with next-generation-
sequencing (NGS) library-construction procedures
for shotgun sequencing with NGS platforms. To
demonstrate the performance of the technique, all
501 exons from 28 genes frequently involved in
cancer were enriched for and sequenced in speci-
mens derived from cell lines and tumor biopsies.
DNA from both fresh frozen and formalin-fixed
paraffin-embedded biopsies were analyzed and
94% specificity and 98% coverage of the targeted
region was achieved. Reproducibility between repli-
cates was high (R
2=0, 98) and readily enabled de-
tection of copy-number variations. The procedure
can be carried out in <24 h and does not require
any dedicated instrumentation.
INTRODUCTION
DNA resequencing of whole mammalian genomes can be
performed with a range of novel sequencing approaches
(1–4). Sufﬁcient coverage to detect the vast majority of
genetic variation in a complete genome can be achieved
with a single instrument run which makes it a very
powerful tool for screening. As discussed below, there
are today also cost-efﬁcient approaches for resequencing
complete exomes, but as sequencing rapidly becomes
cheaper, exome sequencing can be expected to become
less rational. However, for many hypothesis-driven or
clinical investigations, it is more efﬁcient and rational to
direct sequencing to a small fraction of the genome, e.g. to
a set of candidate genes. By limiting the ﬁeld of search,
more sequencing capacity can be spent to achieve high
coverage of the region of interest (ROI). This is particu-
larly useful for investigations where deep sequencing is
required such as sequencing of mosaic tumor biopsies
and for clinical applications. Furthermore, it can also
facilitate analysis of large patient cohorts which is still
very expensive if performed on complete genomes.
Several methods for enrichment of multiple target loci
have been presented. The methods are in the most general
sense based on either hybridization capture or parallelized
PCR ampliﬁcation of multiple regions (5–17). For more
in-depth review of targeted resequencing methodologies,
we refer to the reviews by Mamanova et al. (18) and
Turner et al. (19). Assays based on hybridization have
proven to be effective in capturing the complete exome,
or a large fraction of it. However, relying solely on
hybridization for discrimination between target and
non-target is difﬁcult with regards to speciﬁcity and typic-
ally result in capture of 50–70% irrelevant sequences (6).
The problem is accentuated when capturing smaller
regions that require higher enrichment levels. If the ratio
between on- and off-target DNA is low, the risk of
misaligning off-target sequences to the target sequence
increases, which may lead to false positive, or even false
negative results. This lack of speciﬁcity in the capture step
can to some extent be counteracted in the sequencing
step by increasing the read length and/or performing
paired end sequencing, however this comes at signiﬁcant
increases in both cost and assay time. To allow for a more
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combined with an enzymatic discrimination and ampli-
ﬁcation step, a strategy which is successfully demon-
strated in PCR (20). Since it is difﬁcult to perform highly
multiplex PCR reactions with high-success rate, massive
numbers of single-locus PCRs have to be applied, requiring
compartmentalization in small volumes to be cost-
effective. This can be achieved by array based approaches
(9) or by emulsion PCR (10), both requiring sophisticated
liquid handling and ampliﬁcation systems.
Two approaches have been presented for efﬁcient
single-tube massively multiplexed ampliﬁcation of
genomic loci. Both methods are based on ligase-assisted
DNA-circularization reactions that, similar to PCR, rely
on enzymatic speciﬁcity and dual hybridization recogni-
tion. Gap-ﬁll padlock probes (11) are oligonucleotides
that hybridize with sequences ﬂanking the ROI (e.g.
an exon). The gap between the ends of the probe is ﬁlled
by a DNA polymerase and sealed by a DNA ligase,
creating a circle containing the targeted sequence. With
this approach, tens of thousands of probes have been
ampliﬁed with very low enrichment of off-target
material. However, the performance for exon capture
is less than ideal: at 322  mean coverage only 75% of
the bases were covered at >20  (12). The related
selector probes template circularization of restriction
fragments and do not include synthetic DNA sequences
from the probe in the targeted sequence, thereby reducing
the fraction of irrelevant sequence in the captured DNA.
A PCR-based version of the selector technique was used to
efﬁciently sequence the exons of 11 cancer genes (13) with
excellent speciﬁcity but with relatively high-ampliﬁcation
bias and low coverage (70% coverage at >10  coverage at
127 average coverage).
In orderto retrieve useful sequence information from the
ROI, it is very important that the enrichment is unbiased,
since insufﬁcient or irreproducible coverage within the
target region will drastically lower the fraction of useful
sequence data obtained from an experiment.
In this article, we present a non-PCR-based version
of the selector method (21), including a signiﬁcantly
updated and optimized protocol as well as selector design
approach. Instead of using PCR an RCA-based multiple
displacement ampliﬁcation (MDA) (22) is used, generating
an ampliﬁcation product which is easily integrated with
shotgun library construction for short-read sequencing
platforms.
We evaluate the method for enrichment of a rela-
tively small set of exons (501) with high coverage and
relatively low-enrichment bias. Ampliﬁcation of thou-
sands of targeted fragments (1883) in one tube with
high coverage is demonstrated in a simple process that
does not require genome centers to invest in additional
instrumentation.
MATERIALS AND METHODS
Preparation of tumor samples
Matched fresh-frozen tumor/benign lung tissues and
FFPE tumor tissue were used in accordance with the
Swedish Biobank Legislation and Ethical Review Act
(reference 2006/325, Ethical review board in Uppsala).
The tissue samples were reviewed by a pathologist and
only tumor tissues with a tumor cell fraction >50%
were included. DNA was extracted from FFPE and
frozen tissue sections using the QIAamp DNA Mini Kit
(Qiagen, Hamburg, Germany).
Design and oligonucleotides
Twenty-eight genes (Table 1) known to be mutated in lung
and/or colon cancer were chosen for targeted
resequencing. A list of coding regions for each gene was
downloaded from the consensus coding sequence
database, CCDS (build 36.3) and a total number of 501
regions covering 82kb were targeted. Coding sequences
were collected from hg18 (March, 2006 assembly), and
processed by the Disperse software (23) to generate a set
of restriction fragments using eight combinations of re-
striction enzymes. A subset of 1883 fragments
(Supplementary Table S1) was selected based on length
(100–1000nt), GC-content (20–65%), avoiding repetitive
genomic elements in the ends, and to achieve redundant
coverage over targeted regions. In the current design, we
aimed for a double-fragment redundancy on each targeted
Table 1. Genes included in the design with their corresponding
number of exons and the total number of base pairs that was
aimed to be covered for each gene (ROI)
Number Name Number
of exons
a
Number
of ROI bp
a
Percentage
of ROI bp
covered
a
1 AKT3 14 1685 99
2 IDH1 8 1254 100
3 HER4 28 4124 98
4 CTNNB1 14 2472 100
5 PIK3CA 20 3260 100
6 FBXW7 13 2549 96
7 APC 15 8590 99
8 EGFR 30 4198 100
9 MET 20 4192 100
10 BRAF 18 2432 100
11 CDKN2A 4 1074 100
12 PTEN 9 1359 98
13 CCND1 5 888 100
14 MRE11A 19 2431 99
15 ATM 62 9359 98
16 KRAS 5 687 100
17 HER3 28 4357 98
18 AKT1 13 1594 94
19 SMAD3 9 1352 100
20 TP53 10 1330 100
21 NF1 58 8865 98
22 HER2 31 4357 95
23 SMAD2 10 1485 97
24 SMAD4 11 1778 100
25 STK11
b 9 1370 98
26 CCNE1 11 1357 100
27 AKT2 13 1597 100
28 GNAS 14 2196 98
The last column shows the percentage of the ROI base pairs that were
covered in the design.
aCCDS 14 April 2009.
bNo CCDS available, CDS used, 14 April 2009.
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tions in the restriction enzyme or probe-binding site. The
design achieved  99% coverage of targeted bases and the
missing bases were found to be in or near repetitive
elements. Selected restriction fragments are displayed
in the supplementary gff-ﬁle. Selector probes serving
as template for circularization of each chosen fragment
were designed using the ProbeMaker software (24). Each
selector consists of two Tm balanced sequences of 20–25nt
complementary to the ends of its targeted restriction
fragment.
The oligonucleotides (Integrated DNA Technologies)
hybridizing to 25 bps on each end of the targeted
fragments where pooled in one tube. To add a 30-biotin
to the probes the oligonucleotides where incubated in
2.5mM total concentration with 1  Tdt buffer (NEB),
1  CoCl2 (NEB), 0.1mM dUTP-biotin (Roche
Diagnostics) and 0.2U/ml Terminal Transferase (NEB)
in a ﬁnal volume of 50ml. The reaction was incubated at
37 C for 1h and inactivated at 75 C for 20min. To
remove unincorporated nucleotides the probes were
puriﬁed on three consecutive G-50 columns (GE Life
Sciences).
Restriction digestion
Of each sample, 100ng (200ng for FFPE samples to
compensate for DNA fragmentation) was added to eight
different restriction reactions containing 1 unit each of
two restriction enzymes and their corresponding compat-
ible NEB buffer in 1  concentration and 0.85mg/ml BSA
in a total volume of 10ml. The eight reactions were SfcI
and Hpy188I in NEB buffer 4; DdeI and AluI in NEB
buffer 2; MseI and Bsu36I in NEB buffer 3; MslI and BfaI
in NEB buffer 4; HpyCH4III and Bsp1286 in NEB
buffer 4; SfcI and NlaIII in NEB buffer 4; MseI and
HpyCH4III in NEB buffer 4; HpyCH4V and EcoO109I
in NEB buffer 4 (New England Biolabs). The reactions
were incubated at 37 C for 60min followed by enzyme
deactivation at 80 C for 20min. After this step the eight
reactions were pooled.
Probe hybridization
The 80ml of digested sample resulting from pooling the
reactions were mixed with 10 pM individual concentration
of biotinylated selector probes (Integrated DNA
Technologies), 0.7M NaCl, 7mM Tris–HCl (pH 7.5),
3.5mM EDTA, and 0.07% Tween-20 in a total volume
of 160ml. The solution was incubated at 95 C for 10min,
75 C for 30min, 68 C for 30min, 62 C for 30 min, 55 C
for 30min and 46 C for 10h.
Solid phase capture and wash
To remove off-target material, the hybridization solu-
tion was mixed with 10ml M-280 streptavidin coated
magnetic beads (3.35 10
7 beads/ml; Invitrogen) in
0.7M NaCl, 7mM Tris–HCl (pH 7.5), 3.5mM EDTA
and 0.07% Tween-20 in a ﬁnal volume of 200ml, and
incubated at room temperature for 15min. After incuba-
tion, the beads were collected using a ring magnet.
Following this step, to further remove non-speciﬁcally
bound DNA, the beads were washed in 1M NaCl,
10mM Tris–HCl (pH 7.5), 5mM EDTA and 0.1%
Tween-20 in a total volume of 200mla t4 6  C for 30min
with rotation.
Circularization of targeted fragments
To circularize the genomic fragments, the beads were
incubated in 1  Ampligase reaction buffer, 0.25U/ml
Ampligase (Epicentre) and 0.1mg/ml BSA in a total
volume of 50ml. The ligation mix was incubated at 55 C
for 10min.
Ampliﬁcation
To enrich for circular molecules, a MDA reaction
(Templiphi, GE life sciences) was carried out using the
circles as templates. The circularized molecules were
separated from the beads into the solution by incuba-
tion with 5ml sample buffer at 95 C for 10min and
thereafter collected by placing the tubes in a ring
magnet rack and immediately aspirating the supernatant.
To initiate MDA, 5ml reaction buffer and 0.2ml en-
zyme mix was added to the supernatant and incubated
at 30 C for 4 h followed by deactivation at 65 C for
10min.
Sequencing
Of each MDA-ampliﬁcation product, 300ng was frag-
mented using the Covaris S2 system and libraries where
constructed from these using the SOLiD (v3) library con-
struction kit (Applied Biosystems). The constructed
libraries where sequenced in barcoded sequencing reac-
tions containing 20 different samples on a fourth of a
sequencing slide.
Data analysis
All analyses were made on the targeted 501 exonic regions
deﬁned by CCDS. SOLiD (v3) sequence data from
four specimens, a Yoruba trio (NA1806-8, family Y009),
tumor material from a lung-cancer patient and two
pairs of matched cell lines derived from normal
and breast cancer tissue, were all analyzed by
MosaikAligner version 1.0.1388 (Mosaik—The
MarthLab Available at: http://bioinformatics.bc.edu/
marthlab/Mosaik). MosaikAligner parameters were set
using jump database for mapping to the reference
genome (hg18, mars 2006 assembly); -hs 15, -mm 6, -ms
6, -mhp 100 and -act 20. The alignment software was set to
allow six mismatches per 50-mer read.
Targeted ampliﬁcation speciﬁcity for all samples was
calculated as the proportion of reads that uniquely
aligned to the genome mapped to the targeted region
(Table 2).
SNP array analysis
SNP-array experiments were performed according to the
standard protocols for Affymetrix GeneChip Mapping
NspI-250K arrays (Gene Chip Mapping 500K Assay
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Clara, CA, USA) and the arrays were scanned using the
GeneChip Scanner 3000 7G. Normal samples analyzed
at Uppsala Array Platform were used as a reference set to
produce log ratios. The rank segmentation algorithm,
similar to the Circular Binary Segmentation (CBS) algo-
rithm (25), in the software Nexus from Biodiscovery was
used to segment the data across the genome. The signiﬁ-
cance threshold for segmentation was set at 1 10
 6, also
requiring a minimum of 40 probes per segment. The
results are shown as segmented log2 ratio in Figure 4a.
Copy-number analysis
Copy-number alterations were detected by analyzing the
difference in sequencing depth in each of the targeted pos-
itions with 20  sequencing depth or more in the normal
DNA sample for respective tumor–normal pair. Reference
allele ratios were calculated by dividing reference allele call
frequency by the total sequencing depth for each position
in the targeted region.
To enable comparison of the sequencing and the
GeneChip data (Figure 4b), the sequencing depth log2
ratios were derived from the difference in mean hits per
gene for the normal–tumor pair. They were based on pos-
itions within the ampliﬁed ROI with a sequencing depth of
at least 20  in the normal DNA sample.
Length dependency analysis
To extract junction-speciﬁc reads, a library where two
copies of each selector were concatenated to each other
was created. The reads were aligned to the library and the
reads aligning uniquely over the junction were used as
junction speciﬁc reads.
Analysis of input DNA amount requirement
A titration of different amount of DNA from 100 to
1600ng DNA (combined for all eight restriction diges-
tions) was subjected to our enrichment protocol. The
ampliﬁed DNA was sent to GATC Biotech (Constance,
Germany) for Illumina GAII sequencing. The 32-mer
reads were mapped to our ampliﬁed region as described
above, but only allowing for four mismatches (-mm 4).
The speciﬁcity was calculated as the fraction of unique
reads that mapped to our ampliﬁed region.
RESULTS
We designed a somatic mutation detection assay for 28
genes frequently mutated in solid tumors such as colon,
lung and breast cancer (Table 1), targeting all 501 coding
regions according to the CCDS database, deﬁning our
ROI. The new version of the selector technique is
described in detail in Figure 1a and in brief involves
solid-phase enrichment and probe-templated circulariza-
tion of speciﬁc-restriction fragments that are ampliﬁed
using a circle-speciﬁc RCA-based MDA. The overall
cost and quality of a targeted-sequencing experiment are
determined by the performance of the enrichment tech-
nique. Important metrics to consider are in silico design
coverage, actual coverage, speciﬁcity, reproducibility and
enrichment uniformity across the targeted loci. To
evaluate these parameters, we sequenced a HapMap trio
(NA18506, NA18507 and NA18508) using a SOLiD (v3)
instrument. The sequencing libraries were bar-coded to
allow sequencing of 20 samples on a fourth of a slide.
On average, 899000 reads mapped to the genome, and
of the uniquely mapping reads, 94% (range 92–96%)
mapped to the ampliﬁed region, demonstrating the high
speciﬁcity of this approach corresponding to an
Table 2. Sequencing results for each sample showing the total number of reads obtained for each sample and the percentage of them that align
to the human genome build hg18, and the percentage of the hg18 uniquely aligned reads that aligns to the speciﬁed region
Sample Total
number
of reads
hg18 Ampliﬁed
region
Region
of interest
Region of
interest ±50bp
Percentage
of all reads
a
Percentage
of unique
reads
b
Percentage
of unique
reads
c
Percentage
of unique
reads
c
Percentage
of unique
reads
c
NA18506 1653229 51.34 40.02 92.23 66.21 81.41
NA18507 1709623 50.43 40.16 93.31 67.72 82.99
NA18508 1187613 48.25 38.07 92.82 67.62 82.97
HCC1143 Normal 1687199 51.26 41.23 93.45 67.03 82.38
HCC1143 Tumor 1452999 52.86 43.21 93.85 65.80 81.69
HCC1599 Normal 2617647 53.72 42.48 92.20 65.20 80.45
HCC1599 Tumor 1882203 49.44 41.50 95.61 68.70 85.75
Normal tissue fresh frozen 1567773 53.47 44.27 94.63 67.98 83.42
Tumor tissue fresh frozen 1841970 51.17 42.06 94.32 67.30 83.33
Tumor tissue FFPE 1878918 45.79 37.23 93.95 74.11 88.66
NA18506 2008052 49.63 39.41 92.93 66.98 82.07
All samples 19487226 50.76 40.93 93.55 67.62 83.12
aPercentage of the total number of reads that aligned to the human genome and selector-induced sequences, counting all reads that align (those that
align more than one time is randomly placed and counted only once).
bPercentage of the total number of reads that aligned uniquely to hg18.
cPercentage of the uniquely aligned reads to hg18 that aligned uniquely to the region speciﬁed.
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off ROI)/(size of ROI/size of the genome)] of 200000
(enrichment statistics for all samples are summarized in
Table 2). Some ampliﬁed fragments will also contain
adjacent off ROI sequence. With a strict coding-sequence
target deﬁnition, 68% of the reads mapped on target, and
83% on target ±50bp. The reproducibility in coverage
between samples is illustrated in Figure 1b and was
calculated to 0.98 (R
2, linear regression). Furthermore,
98% of the targeted bases were covered at >10% of the
mean base coverage (mean coverage=273, Figure 1c and
Supplementary Figure S1). To investigate how much input
DNA is required for the method, we performed
enrichment experiments on different amounts of
template DNA (Table 3). We observed that the speciﬁcity
decreased when <800-ng DNA was added to the reaction,
and therefore we chose not to use less DNA than 800ng
per sample in this study.
It is of great importance that an enrichment tech-
nique introduces minimal distortion of the original
allele ratios in the analyzed sample. To assess the
ability of the presented Selector protocol to preserve
original allele ratios, we sequenced a HapMap trio
Figure 1. Selector probe technology and performance. (a) Overview of the selector-probe ampliﬁcation procedure. A ROI (e.g. an exon) is targeted
by probing several redundant fragments (dark blue) selected from eight separate restriction digestion reactions of a genomic DNA sample (light
blue). The restriction-digested DNA samples are pooled and hybridized with biotin-tagged selector probes complementary to the ends of each
targeted restriction fragment (red). The targeted fragments are then captured on streptavidin-coated magnetic beads. The fragments are circularized
by DNA ligation after removal of non-targeted DNA. Finally, the circularized fragments are released from the beads and speciﬁcally ampliﬁed using
the RCA-based MDA. (b) Correlation of the relative coverage of individual bases between two replicate enrichment and sequencing experiments.
(c) The cumulative fraction of the target sequence covered is plotted as a function of different relative read-depths, indexed to the mean coverage, in
three sequencing experiments using DNA from the NA18506 HapMap cell line (black line), fresh-frozen lung cancer tissue (blue broken line) and
FFPE lung cancer tissue (red broken line).
Table 3. Speciﬁcity values obtained for experiments with different
amount of input DNA
Input DNA (ng) Speciﬁcity
a (%)
1600 96.0
800 91.0
400 83.9
200 75.0
100 66.0
aPercentage of the uniquely aligned reads to hg18 that aligned uniquely
to the region speciﬁed.
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our calls with results made available within the HapMap
project (26). Reference allele-frequency analysis was
performed using MosaikAligner and the result was
compared to the genotypes of the 164 available SNPs in
the target sequence in the HapMap database which
overlapped with the ROI (Figure 2 and Table 4). The
concordance was 100% for covered SNPs within ROI
and 99% including targeted SNPs outside of ROI
(in total 383).
To investigate the utility of this enrichment technique
for analysis of somatic mutations in cancer, we sequenced
tumor and matched control samples of two breast-cancer
cell lines (HCC1143 and HCC1599). By comparing the
variant calls from the tumor and the matched normal
tissue, it is possible to distinguish germline variants from
somatic mutations. The results from comparing allele
ratios are plotted in the lower panels of Figure 3a and b
and the calls are summarized in Table 5. The difference in
allele ratio between the tumor and normal cell line was
>0.3in14ROIpositionsinHCC1143,and7ROIpositions
in HCC1599. The differences in HCC1143 were due
to loss-of-heterozygosity (LOH) in eight genes, caused by
allelic ampliﬁcation (CCND1), deletion [MET, CDKN2A,
MRE11A, ATM, NF1 and ERBB2 (HER2)] and copy-
number neutral LOH (uniparental disomy, APC). An
(A!G) mutation was found in the HER3 gene outside
the ROI. The allele-ratio differences in HCC1599 were
due to LOH in ﬁve genes, caused by allelic ampliﬁcation
(CCNE1) and deletions (APC, EGFR, TP53 and NF1).
Finally, one (T!A) mutation in the TP53 gene was
identiﬁed just outside the ROI in association with loss of
the normal allele, which conﬁrms a previous study of
the somatic mutation spectrum in this cell line (27). In
addition to mutation detection, we also compared the
relative read depth at different positions in the ROI to
detect copy-number alterations. Comparison of relative
read depth at each position in the ROI in the cell
line pairs HCC1143/HCC1143BL and HCC11599/
HCC11599BL are plotted in upper panels in Figure 3a
and b, respectively. To exclude that the differences in
coverage originated from poor reproducibility of the
assay, we also analyzed a replicate sequencing experiment
of the NA18506 DNA sample in the same manner
(Figure 3c). The analysis revealed considerable relative
copy-number variation between the tumor and normal
cell line, including ampliﬁcation, duplication or deletion
of the majority of investigated genes.
Finally, we evaluated the technique on DNA prepared
from normal and tumor tissue from a lung-cancer patient.
We applied the same subtractive approach to analyze the
mutational status of the 28 genes as with the cancer cell
line samples. We detected copy-number deviations that
conﬁrmed previous microarray analysis performed using
an Affymetrix 250K SNP chip (Figure 4a, Supplementary
Figure S2). The deviations were smaller in this experi-
ment than for the cell lines, which is consistent with a
tumor-cell content of  50% in this sample. The correl-
ation between the array-based copy-number estimate
and our sequencing-based estimate proved to be strong
(R
2=0.9999) (Figure 4b). We detected a single base-pair
deletion that had previously been identiﬁed in the TP53
gene by Sanger sequencing (28) (Figure 4c). The majority
of patient tumor samples are prepared and stored as
formalin-ﬁxed parafﬁn embedded (FFPE) specimens.
The potential utility of a somatic mutation analysis
technique is therefore greatly enhanced if it is compat-
ible with DNA from FFPE tissue samples, which are
often severely degraded. To evaluate this potential we
ampliﬁed and sequenced the 28 genes using DNA from
an FFPE sample from the same lung cancer patient.
We found the TP53 deletion mutation also in this
material (Figure 4d). By quantifying the reads mapping
Figure 2. Analysis of concordance with available SNP genotypes of the
(a) NA18506; (b) NA18507; and (c) NA18508 DNA samples. The allele
ratio of all positions where the SNP genotype is available in the
HapMap database are plotted as a function of read depth. Green
dots represent homozygous SNP positions in the database and red
dots represent heterozygous positions. Heterozygous positions were
deﬁned as having an allelic ratio of  0.35 and  0.85 (dashed horizontal
lines). The vertical dashed line indicates a read depth of 20.
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to retrieve information about the performance of indi-
vidual selectors. We observed worse representation
of the longer fragments than the shorter in the FFPE
sample compared to the fresh frozen (Figure 5), resulting
in more uneven ampliﬁcation (Figure 1c). However,
the difference in coverage between the shortest and the
longest fragments in the range 100–300bp was less than
a factor of two, so with a different probe design targeting
shorter fragments, evenness of coverage should be
improved.
DISCUSSION
In this article, we report on a method for targeted enrich-
ment of a relatively small subset of genes that produces
the targeted regions in an unbiased fashion with very low
amount of off-target material. For a small set of samples,
it would be possible to sequence the same region with
PCR and Sanger sequencing with an estimated 384-well
plate of reactions for each sample. We are however
convinced that the proposed scheme is more practical
also for small collections of samples.
Compared to the previously published version of
the selector technology (13,29), the current protocol
uses MDA instead of PCR. By eliminating the PCR
primers in the probes, the oligonucleotide length, and
thereby also cost, is signiﬁcantly reduced. Probe cost
has further been reduced through the introduction of
a solid-phase puriﬁcation step to remove excess probe
molecules, replacing the enzymatic degradation used in
the previous protocol, requiring expensive uracil residues
in the probes. The invasive cleavage that was used to
generate the majority of fragments in the previous
protocol was avoided in this version, since we observed
worse bias when it was used (data not shown). Thus
in this study, we only used restriction digestion to
generate the fragments. We have further increased
design redundancy, which should improve coverage. It is
difﬁcult to assess whether MDA introduce less or more
ampliﬁcation bias compared to PCR, because of
the probe redundancy and since different sequencing
platforms were used to sequence the PCR amplicons
(454, long read) and the MDA products (SOLiD, short
read). In contrast to PCR, the MDA ampliﬁcation gener-
ates a double-stranded high-molecular weight ampliﬁ-
cation product that is very similar in nature to genomic
DNA. We have demonstrated compatibility with the
standard sample preparation procedures for both SOLiD
and Illumina short-read instruments. In contrast, to be
compatible with the short-read-sequencing platforms, a
PCR product requires concatemerization by ligation,
followed by fragmentation, which is a more complicated
scheme. For emulsion PCR, an additional fragmentation
step is also required before the PCR resulting in a very
laborious procedure. The MDA also avoids clonal propa-
gation of polymerization artifacts by employing rolling
circle ampliﬁcation, a feature valuable for detection of
rare variants.
In addition to the importance of maintaining high
speciﬁcity, only enriching regions that are targeted, it is
also important to minimize the number of near-target base
pairs that are ampliﬁed. The restriction enzyme-based
approach of the selector technology provides very high-
on-target rate by design, between 50–70% of the
amplicons are on exons in the majority of designs (30).
This is comparable and even slightly better than published
work using parallel PCR on the Raindance platform (10).
In this article exons with an average size of 167bp where
targeted with amplicons of between 300 and 600bp, which
will generate a signiﬁcant proportion of near-exon
sequence. The selector amplicons range between 100 and
1000 and can more easily be adjusted to ﬁt the target
length when selecting from eight different restriction
enzyme reactions (30).
Multiplex targeted sequencing is of particular interest
for molecular cancer diagnostics as genetic aberra-
tions in growth-factor-signaling pathways can be decisive
Table 4. SNP concordance with data available from three HapMap samples (NA18506, NA18507 and NA18508) at two coverage thresholds:
covered at least once and covered at least 20 times
Sample Relation Coverage Region Number
of SNPs
a
Covered (%) Homozygote
b Heterozygote Concordance (%)
Selectors Hapmap Selectors Hapmap
NA18506 Son  1  ROI 165 100.00 161 161 4 4 100.00
Ampliﬁed region 382 99.21 346 347 33 32 99.74
 20  ROI 165 91.52 147 147 4 4 100.00
Ampliﬁed region 382 75.39 265 265 23 23 100.00
NA18507 Father  1  ROI 164 100.00 151 151 13 13 100.00
Ampliﬁed region 382 99.21 330 326 49 53 98.42
 20  ROI 164 92.07 138 138 13 13 100.00
Ampliﬁed region 382 74.87 248 249 38 37 99.65
NA18508 Mother  1  ROI 165 100.00 151 151 14 14 100.00
Ampliﬁed region 383 98.96 334 329 45 50 98.68
 20  ROI 165 80.61 122 122 11 11 100.00
Ampliﬁed region 383 62.92 211 211 30 30 100.00
Positions are considered as heterozygote if the reference allele ratio is between 0.35 and 0.85.
aNumber of HapMap SNPs overlaping with region. NN positions omitted.
bReference allele ratio under 0.35 or above 0.85.
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genes have to be analyzed separately in an old pipeline
using PCR followed by Sanger sequencing, the diag-
nostic process becomes time-consuming and costly.
Also, as tumor material often is limited, e.g. in the
form of small biopsies, it is difﬁcult to obtain
sufﬁcient DNA for a multitude of separate targeted-
mutation assays. The current selector protocol con-
sumes only 800ng of genomic DNA. We believe that
this method can be useful for clinical diagnostics since it
can be applied on routinely collected FFPE samples.
The Selector probe set used in this study enriched
for nearly all bases within the ROI except for only 1.4%
(30 regions) of the bases being unavailable applying the
current design criteria. When using targeted sequencing
for diagnostic purposes, it is often important to be
able to analyze all bases within the ROI that can be
uniquely mapped with the read length produced by the
sequencing instrument. The bases that we failed to cover
with selected fragments either contained repetitive
elements or SNPs in the hybridization sites. To achieve
complete coverage, manual examination of the failed
regions enables us to allow some fragments back into
the design that have been previously rejected by the
restrictive design ﬁlters.
Targeted resequencing is expected to be one of the
major applications for next-generation sequencing. The
current high-throughput platforms are in some aspects
suboptimal for targeted resequencing. To meet the
demand of quick and simple sequencing, several scaled
down sequencing platforms have been announced (e.g.
454 GS Junior, iScan and Ion Torrent), and to harness
the power of these instruments, simple, efﬁcient and
high-quality enrichment technologies are needed. We
present a technology that offers high-performance
targeted analyses using a simple and scalable protocol.
To our knowledge, this is the only procedure for
scalable multiplex enrichment of targets that achieves
high (>95%) coverage and high (>95%) speciﬁcity
without introducing requirements of dedicated instrumen-
tation. Versions of the technology enabling introduction
of sequencing primers and barcodes during ampliﬁcation
are under development. So far, direct library free
amplicon sequencing has been limited to the 454
sequencing platform, however, development of existing
and new platforms will make this an attractive option
for several sequencing technologies.
Figure 3. Somatic mutation analysis of two breast cancer cell lines with
matched normal controls HCC1143/HCC1143BL (a) and HCC1599/
HCC1599BL (b). In each position in the targeted region, the number
of bases called in the matched normal cell line (HCC1143BL/
HCC1599BL) is subtracted from the number of bases called in the
tumor-derived cell line (HCC1143/HCC1599) and then divided with
the sum of called bases for that position in the two samples. The
exons of the 28 genes are concatenated in the order speciﬁed in
Table 1 and gene shifts are demarked by alternating background
color. The lower panels show the value obtained from each base
when the allelic ratio between the major and minor allele of the
normal sample is subtracted from the corresponding allelic ratio of
the tumor sample. (c) Base-by-base comparison of two replicate
sequencing experiments of the cell line NA18506.
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e8 Nucleic AcidsResearch, 2011,Vol. 39,No. 2 PAGE 10 OF 13Figure 4. (a) Mutation detection and CNV analysis of a lung cancer patient sample with matched control. Upper panel: for each position in the
targeted region the number of bases called in the patient-matched normal tissue is subtracted from the number of bases called in the tumor-derived
DNA, and then divided with the sum of called bases for that position in the two samples. The exons of the 28 genes are lined up after each other and
genes are demarked by alternating background color. Middle panel: the inferred gene copy-number variation in the corresponding genomic loci
illustrated by log2 ratios (pink line) derived from SNP array data (Affymetrix Gene Chip Mapping 250K arrays). Middle panel: the log2 ratio (pink
line) of the copy-number analysis done on an Affymetrix micro array. Lower panel: the allelic ratio between the major and minor allele at each
position is compared between the two samples by subtraction (b). A correlation plot between the Affymetrix Gene Chip log2 tumor/normal signal
ratio and the log2 tumor/normal sequencing read depth ratio. (c) Detection of a single base pair deletion in the TP53 gene. Forward (brown) and
reverse (blue) reads are aligned to a 15-bp region of the TP53 gene. Deleted bases are indicated by dashed lines. Alignment visualized in Integrative
Genomic Viewer (IGV ver.1.4.2). (d) Detection of the same mutation in the FFPE sample from the same tumor.
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